Merge

Merge Therapeutics is an early-stage biotechnology company focused on developing a novel class of trispecific antibodies for the treatment of autoimmune and inflammatory diseases. The company's proprietary platform is designed to achieve deep depletion of pathogenic cells, addressing the limitations of current therapies and aiming to provide more durable clinical outcomes for patients with chronic inflammatory conditions. Founded in 2024 and led by CEO Lauren Gehman, Merge Therapeutics is a winner of the Mission BioCapital Platinum Ticket and has secured backing from prominent investors including Roche Venture Fund and Eli Lilly. The company is currently in the pre-clinical stage and operates out of the MBC BioLabs incubator in the San Francisco Bay Area.